GLP-1 agonists, DPP-4 inhibitors off the hook, for now
This article was originally published in Scrip
Executive Summary
There is currently no evidence that GLP-1 agonists and DPP-4 inhibitors lead to a heightened risk of pancreatic adverse events, says the European Medicines Agency's Committee for Medicinal Products for Human Use. The CHMP has recently concluded a review of the products and found that a study that sparked concerns was limited in several ways.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.